FrancophonIA/ELRC3.0 huggingface dataset:
English: Thrombocytopenia
Estonian: • Kopsutromb
English: Dynastat 40 mg powder for solution for injection Parecoxib
Estonian: Dynastat 40 mg süstelahuse pulber parekoksiib
English: Powder for solution for injection (powder for injection).
Estonian: Süstelahuse pulber (süstepulber).
English: IV line solution compatibility
Estonian: Lahuse sobivus veeniinfusioonisüsteemi
English: Dynastat 40 mg powder for solution for injection
Estonian: Dynastat 40 mg süstelahuse pulber
English: Ear pain
Estonian: • Kõrvavalu
English: Posology
Estonian: Seedetrakt
English: GENERAL CLASSIFICATION FOR SUPPLY
Estonian: Valmislahuse valmistamine
English: Thus, 24 hours should be considered the maximum shelf life of the reconstituted product.
Estonian: Manustamiskõlblikuks muudetud ravimi maksimaalne kõlblikkusaeg on 24 tundi.
English: Concomitant use with opioid analgesics
Estonian: • Flukonasool - kasutatakse seeninfektsioonide korral
English: 3 x (1 vial + 1 prefilled syringe + 1 plunger rod + 1 vial adapter + 1 needle) (multipack)
Estonian: 3 x (1 viaal + 1 süstel + 1 kolvivars + 1 viaali adapter + 1 nõel) (mitmikpakend)
English: 2 vials +2 pre-filled syringes +2 plunger rods + 2 vial adapters + 2 needles
Estonian: 2 viaali +2 süstelit +2 kolvivart + 2 viaali adapterit + 2 nõela
English: 1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 needle
Estonian: 1 viaal +1 süstel +1 kolvivars + 1 viaali adapter +1 nõel
English: MA (EU) Number Invented name Strength Pharmaceutical Form Route of Administration
Estonian: Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus
English: The maximum dose is one tablet of the highest strength (80/10 mg) once a day.
Estonian: Suurim annus on üks suurima tugevusega tablett (80/10 mg) üks kord ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the EU for Twynsta on 7 October 2010.
Estonian: Euroopa Komisjon andis Twynsta müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. oktoobril
English: Both are medicines to lower the blood pressure that have been available in the European Union (EU) since the 1990s.
Estonian: Mõlemad ravimid alandavad vererõhku ja neid on turustatud Euroopa Liidus alates 1990. aastatest.
English: It is available as tablets (40 mg telmisartan/10 mg amlodipine, 40 mg telmisartan/5 mg amlodipine, 80 mg telmisartan/10 mg amlodipine and 80 mg telmisartan/5 mg amlodipine).
Estonian: Seda turustatakse tablettidena (40 mg telmisartaani / 10 mg amlodipiini, 40 mg telmisartaani / 5 mg amlodipiini, 80 mg telmisartaani / 10 mg amlodipiini ja 80 mg telmisartaani / 5 mg amlodipiini).
English: When appropriate, direct switch to Twynsta may be considered.
Estonian: Vajaduse korral võib kaaluda kohest üleminekut Twynstale.
English: Twynsta is taken by mouth as one tablet once a day and is used for long-term treatment.
Estonian: Twynstat manustatakse suu kaudu üks tablett ööpäevas ning seda kasutatakse pikaajaliseks raviks.
English: Twynsta telmisartan / amlodipine
Estonian: Twynsta telmisartaan/amlodipiin
English: The main measure of effectiveness in the three studies was the fall in diastolic blood pressure (blood pressure measured between two heartbeats) after eight weeks.
Estonian: Efektiivsuse põhinäitaja oli kõigis kolmes uuringus diastoolse vererõhu (vererõhk südamelöökide vahelisel ajal) alanemine kaheksa nädala pärast.
English: Because telmisartan and amlodipine have been used for many years, the company presented information from scientific literature as well as results from new studies that the company had carried out.
Estonian: Et telmisartaani ja amplodipiini on kasutatud palju aastaid, esitas ettevõte teaduskirjandusest ja samuti ettevõtte tehtud uuringutest pärit andmed.
English: The Committee decided that Twynsta's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Twynsta kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Twynsta.
Estonian: See on ravimi Twynsta Euroopa avaliku hindamisaruande kokkuvõte.
English: In the two other studies, Twynsta was more effective at reducing diastolic blood pressure than continued treatment with amlodipine alone: depending on the strengths of Twynsta and amlodipine, the fall in diastolic blood pressure was greater in patients taking Twynsta by between 1.4 mmHg and 4.9 mmHg.
Estonian: Ülejäänud kahes uuringus alandas Twynsta diastoolset vererõhku efektiivsemalt kui ravi jätkamine ainult amlodipiiniga: olenevalt Twynsta ja amlodipiini annuse tugevusest alanes diastoolne vererõhk Twynstat kasutanud patsientidel 1,4-4,9 mmHg võrra rohkem.
English: Twynsta must not be used in patients who have severe liver or bile problems, shock (a steep fall in blood pressure), obstruction to blood flow from the left side of their heart or in patients with heart failure after having a myocardial infarction (heart attack).
Estonian: Twynstat ei tohi kasutada patsiendid, kellel on rasked maksa- või sapiprobleemid, šokk (vererõhu järsk langus), südame vasaku poole verevarustuse häired või südamepuudulikkusega patsiendid pärast müokardiinfarkti (südameinfarkt).
English: In addition, studies showed that the medicine was effective in patients whose blood pressure is not adequately controlled by amlodipine alone.
Estonian: Lisaks näitasid uuringud, et ravim on efektiivne patsientidel, kelle vererõhk ei allu piisavalt ravile ainult amlodipiiniga.
English: Twynsta can also be used in place of treatment with telmisartan and amlodipine in patients who are taking both medicines as separate tablets.
Estonian: Twynstat tohib kasutada ka telmisartaani ja amlodipiini ravi asemel patsientidel, kes võtavad mõlemaid ravimeid eraldi tablettidena.
English: The most common side effects with Twynsta (seen in up to 1 patient in 10) are dizziness and peripheral oedema (swelling, especially of the ankles and feet).
Estonian: Twynsta kõige sagedamad kõrvalnähud (esinenud kuni 1 patsiendil 10st) on peapööritus ja perifeerne ödeem (jäsemete, tavaliselt labajalgade turse).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Twynsta.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Telmisartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: The CHMP noted that patients already taking the two active substances in separate tablets may be more likely to adhere to their treatment if prescribed Twynsta.
Estonian: Inimravimite komitee märkis, et patsiendid, kes kasutavad kaht toimeainet eraldi tablettidena, järgivad Twynsta määramisel raviskeemi tõenäoliselt rohkem.
English: Twynsta is used in patients whose blood pressure is not adequately controlled by amlodipine alone.
Estonian: Twynstat kasutatakse patsientidel, kelle vererõhk ei ole ainult amlodipiiniga piisavalt reguleeritav.
English: In one main study, 1,461 adults with hypertension were treated with combinations of telmisartan and amlodipine, with telmisartan or amlodipine alone, or with placebo (a dummy treatment).
Estonian: Ühes põhiuuringus said 1461 hüpertensiooniga täiskasvanud patsienti kombineeritud ravi telmisartaani ja amlodipiiniga, ainult telmisartaani või amlodipiini, või platseebot (näiv ravim).
English: By blocking the receptors to which angiotensin II normally attaches, Telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Estonian: Blokeerides retseptorid, millega angiotensiin II tavaliselt seondub, peatab telmisartaan hormooni toime ja soodustab veresoonte laienemist.
English: For the full list of all side effects reported with Twynsta, see the package leaflet.
Estonian: Twynsta kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Twynsta must not be used in people who may be hypersensitive (allergic) to telmisartan, amlodipine, other medicines in the ‘dihydropyridine derivatives' class or to any of the other ingredients.
Estonian: Twynstat ei tohi kasutada patsiendid, kes võivad olla amlodipiini, telmisartaani, teiste dihüdropüridiini derivaatide klassi kuuluvate ravimite või selle ravimi mis tahes muude koostisainete suhtes ülitundlikud (allergilised).
English: For a patient whose blood pressure is not adequately controlled by amlodipine, separate tablets of amlodipine and telmisartan should be used to adjust the doses before switching to Twynsta.
Estonian: Patsientidele, kelle vererõhku ei saa amlodipiiniga piisavalt reguleerida, tuleb anda amlodipiini ja telmisartaani tablette eraldi, et kohandada annuseid enne Twynstale üleminekut.
English: Twynsta is used to treat essential hypertension (high blood pressure) in adults (aged 18 years or over).
Estonian: Twynstat kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks vähemalt 18aastastel täiskasvanud patsientidel.
English: Other information about Twynsta:
Estonian: Muu teave Twynsta kohta
English: In two other main studies, 1,978 adults whose hypertension had not responded adequately to amlodipine were either given Twynsta or continued to take amlodipine at the same or a higher dose.
Estonian: Veel kahes põhiuuringus, milles osales 1978 täiskasvanud patsienti, kelle hüpertensioon ei allunud piisavalt ravile amlodipiiniga, anti patsientidele Twynstat või nad jätkasid senist ravi amlodipiini sama või suurema annusega.
English: What is the risk associated with Twynsta?
Estonian: Mis riskid Twynstaga kaasnevad?
English: Why has Twynsta been approved?
Estonian: Miks Twynsta heaks kiideti?
English: Twynsta is a medicine that contains two active substances, telmisartan and amlodipine.
Estonian: Twynsta on ravim, mis sisaldab kaht toimeainet: telmisartaani ja amlodipiini.
English: Twynsta contains two active substances, telmisartan and amlodipine.
Estonian: Twynsta sisaldab kaht toimeainet: telmisartaani ja amlodipiini.
English: For a patient who has been taking telmisartan and amlodipine as separate tablets, the dose of Twynsta to be taken depends on the doses of telmisartan and amlodipine that he or she was taking before.
Estonian: Patsientidel, kes on võtnud telmisartaani ja amlodipiini eraldi tablettidena, sõltub Twynsta annus varem võetud telmisartaani ja amlodipiini annustest.
English: The full EPAR for Twynsta can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Twynsta kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports Kui vajate Twynstaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Twynsta?
Estonian: Mis on Twynsta?
English: In the first study, the falls in diastolic blood pressure seen in patients taking combinations of telmisartan and amlodipine were greater than those seen in patients taking only one of the active substances or placebo.
Estonian: Esimeses uuringus alanes telmisartaani ja amlodipiini kombinatsiooni manustanud patsientidel diastoolne vererõhk rohkem kui ainult üht toimeainet või platseebot manustanud patsientidel.
English: Studies were also carried to show that Twynsta tablets are absorbed in the same way in the body as separate tablets of amlodipine and telmisartan.
Estonian: Tehti ka uuringuid eesmärgil selgitada, kas Twynsta ning amlodipiini ja telmisartaani tabletid imenduvad organismis ühtmoodi.
English: How is Twynsta used?
Estonian: Kuidas Twynstat kasutatakse?
English: What is Twynsta used for?
Estonian: Milleks Twynstat kasutatakse?
English: What benefit has Twynsta shown during the studies?
Estonian: Milles seisneb uuringute põhjal Twynsta kasulikkus?
English: Twynsta must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Estonian: II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Twynstat koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: How does Twynsta work?
Estonian: Kuidas Twynsta toimib?
English: How has Twynsta been studied?
Estonian: Kuidas Twynstat uuriti?
English: ATCvet code: QI06AH09.
Estonian: ATCvet kood: QI06AH09
English: Date of first authorisation: 23/02/2005 Date of last renewal: 25/01/2010
Estonian: Esmase müügiloa väljastamise kuupäev : 23/02/2005 Müügiloa pikendamise kuupäev: 25/01/2010
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljel (http://www.ema.europa.eu/ )
English: Store and transport refrigerated (2 °C - 8 °C).
Estonian: Hoida ja transportida külmas (2°C -8°C).
English: Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg :18 kuud.
English: Special precautions for use in animals: Use in healthy animals only.
Estonian: Ettevaatusabinõud kasutamisel loomadel: Kasutada ainult tervetel loomadel.
English: EXP (mm/yyyy) Once reconstituted use immediately.
Estonian: EXP: (/kuu/aasta) Pärast lahustamist kasutada koheselt.
English: EU/2/04/052/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/052/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
Estonian: EU/2/04/052/001 lüofilisaat (10 pudelit, igas 1 doos) + lahus (10 pudelit, igas 1 doos) EU/2/04/052/002 lüofilisaat (50 pudelit, igas 1 doos) + lahus (50 pudelit, igas 1 doos)
English: Incompatibilities: Do not mix with Merial adjuvanted vaccine against rabies.
Estonian: Sobimatus: Mitte segada Merial marutaudi vastase adjuveeritud vaktsiiniga.
English: Do not mix with Merial adjuvanted vaccine against rabies.
Estonian: Mitte segada Merial marutaudi vastase adjuveeritud vaktsiiniga.
English: Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs.
Estonian: 8-nädalaste ja vanemate kassipoegade aktiivne immuniseerimine: - kasside viraalse rinotrahheiidi vastu, et vähendada kliinilisi tunnuseid - kalitsiviirusinfektsiooni vastu , et vähendada kliinilisi tunnuseid.
English: No effects other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
Estonian: Ei ole täheldatud muid kõrvaltoimeid peale nende, mis on ära toodud punktis “Kõrvaltoimed”, välja arvatud erandjuhtudel esinev hüpertermia, mis võib kesta kuni 5 päeva.
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administrated with Merial non-adjuvanted vaccine against feline leukaemia and/or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Estonian: Olemasolevad ohutuse ja efektiivsuse andmed , mis näitavad, et antud vaktsiinipreparaati võib segada ja manustada koos Meriali mitteadjuveeritud vaktsiiniga kasside leukeemia vastu ja/või manustada samal päeval kuid mitte kokku segatuna Meriali adjuveeritud marutaudi vastase vaktsiiniga .
English: Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:
Estonian: Süstida subkutaanselt üks doos (1 ml) vaktsiini pärast külmkuivatatud tableti lahustamist lahustiga järgneva vaktsineerimisskeemi järgi:
English: Per 1 ml dose:
Estonian: 1 ml doos sisaldab:
English: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50 FCV (431 and G1 strains) ............................................................................................... ≥ 2.0 ELISA U. FPV (PLI IV) .................................................................................................................... ≥ 103.5 CCID50.
Estonian: FHV (tüvi F2) .................................................................................................................... ≥ 104.9 CCID50 FCV(tüved 431 ja G1) ..................................................................................................... ≥ 2.0 ELISA U. FPV (PLI IV) ...................................................................................................................... ≥ 103.5 CCID50
English: Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Estonian: 9-12 nädala vanused kassipojad, kelle emad on vaktsineeritud enne tiinestumistja/või teadaolev või kahtlustatav kokkupuude patogeeni(de)ga) tuleks esmase vaktsineerimiskuuri algus lükata edasi kuni 12. elunädalani.
English: Name and address of the manufacturers of the biological active substances
Estonian: Bioloogiliselt aktiivset) ainete tootjate nimed ja aadressid:
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Estonian: A. BIOLOOGILISTE TOIMEAINETE TOOTJAD JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV TOOTJA
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Pack of 10 bottles of lyophilisate and 10 bottles of solvent Pack of 50 bottles of lyophilisate and 50 bottles of solvent
Estonian: Pakend 10 pudelit lüofilisaati ja 10 pudelit lahustit Pakend 50 pudelit lüofilisaati ja 50 pudelit lahustit
English: Revaccination: - the first revaccination must be carried out one year after the primary vaccination course, - subsequent revaccinations must be carried out at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Estonian: Kordusvaktsineerimine: - esimene kordusvaktsineerimine 1 aasta pärast esmast vaktsineerimist, - järgnevad kordusvaktsineerimised rinotrahheiidi, kalitsiviiruse ja panleukopeenia komponentide suhtes viiakse läbi kuni 3 aastase intervalliga.
English: The duration of immunity after the last re-vaccination is 3 years for rhinotracheitis, calicivirosis and panleucopenia components.
Estonian: Imuunsuse kestus pärast viimast (re)vaktsineerimist on rinotrahheiidi, kalitsiviiruse, ja panleukopeenia komponentide suhtes 3 aastat.
English: Disodium hydrogen orthophosphate Monopotassium phosphate anhydrous
Estonian: Dinaatrium vesinik ortofosfaat Anhüdreeritud monokaalium fosfaat
English: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Estonian: Kasside nõrgestatud rinotrahheiidi herpesviirus (FHV F2 tüvi) ..................................... ≥ 104.9 CCID501 Kasside inaktiveeritud kalitsiviirus (FCV 431 ja G1 tüvi) antigeenid ........................... ≥ 2.0 ELISA U. Kasside nõrgestatud panleukopeenia viirus (PLI IV) ..................................................... ≥ 103.5 CCID501
English: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Estonian: Kasside nõrgestatud rinotrahheiidi herpesviirus (FHV F2 tüvi) ..................................... ≥ 104.9 CCID501 Kasside inaktiveeritud kalitsiviirus (FCV 431 ja G1 tüvi) antigeene ............................. ≥ 2.0 ELISA U. Kasside nõrgestatud panleukopeenia viirus (PLI IV) ..................................................... ≥ 103.5 CCID501
English: CONTRAINDICATIONS
Estonian: Näidustused
English: No effect other than those already mentioned in section on “Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days.
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid: mitmekordse annuse manustamist ei ole täheldatud muid kõrvaltoimeid peale nende, mis on ära toodud punktis “Kõrvaltoimed”, välja arvatud erandjuhtudel esinev hüpertermia, mis võib kesta kuni 5 päeva.
English: Manufacturer responsible for the batch release: MERIAL
Estonian: Partii vabastamise eest vastutav tootja MERIAL,
English: Solvent:
Estonian: Abiained::
English: Purevax RCP lyophilisate and solvent for suspension for injection.
Estonian: Purevax RCP lüofilisaat ja lahusti süstesuspensiooni valmistamiseks
English: Onsets of immunity have been demonstrated 1 week after primary vaccination course for the rhinotracheitis, calicivirus and panleucopenia components.
Estonian: Immuunsus tekib 1 nädal pärast esmast vaktsineerimiskuuri rinotrahheiidi, kalitsiviiruse ja panleukopeenia vastu.
English: Purevax RCP lyophilisate and solvent for suspension for injection
Estonian: Purevax RCP; lüofilisaat ja lahusti süstesuspensiooni valmistamiseks
English: Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, and feline panleucopenia virus.
Estonian: Kutsub esile immuunsuse kasside rinotrahheiiti põhjustava herpesviiruse, kasside kalitsiviiruse, ja kasside leukeemia vastu.
English: 1 ml 1 cell culture infective dose 50%.
Estonian: Süstevesi ........................................................................................................................................ q.s 1 ml 1 rakukultuuri infektiivne doos 50%
English: In terms of safety, the side effects were considered acceptable or manageable.
Estonian: Ohutuse seisukohast peeti kõrvalnähte vastuvõetavaks või hallatavateks.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Moventig on 8 December 2014.
Estonian: Euroopa Komisjon andis Moventigi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 8. detsembril 2014.
English: What measures are being taken to ensure the safe and effective use of Moventig?
Estonian: Mis meetmed võetakse, et tagada Moventigi ohutu ja efektiivne kasutamine?
English: The full EPAR and risk management plan summary for Moventig can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Moventigi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Moventig is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Moventigi võimalikult ohutu kasutamine.
English: What is Moventig and what is it used for?
Estonian: Mis on Moventig ja milleks seda kasutatakse?
English: Although studies in patients with cancerrelated pain had not been conducted, based on the mechanism of action of the medicine, the benefit for these patients was not expected to be different but the safety should be closely monitored.
Estonian: Kuigi vähivaluga patsientidel ei ole uuringuid toimunud, ei eeldata ravimi toimemehhanismi alusel, et kasulikkus nendel patsientidel oleks teistsugune, kuid ohutust tuleb tähelepanelikult jälgida.